Evolutionary fitness landscapes of certain antibiotic target enzymes have been comprehensively 16 mapped showing strong high order epistasis between mutations, but understanding these effects 17 at the biochemical and molecular levels remained open. Here, we carried out an extensive 18 experimental and computational study to quantitatively understand the evolutionary dynamics of 19 Escherichia coli dihydrofolate reductase (DHFR) enzyme in the presence of trimethoprim induced 20 selection. Biochemical and structural characterization of resistance-conferring mutations targeting 21 a total of ten residues spanning the substrate binding pocket of DHFR revealed distinct resistance 22 mechanisms. Next, we experimentally measured biochemical parameters (K m , K i , and k cat ) for a 23 mutant library carrying all possible combinations of six resistance-conferring DHFR mutations and 24 quantified epistatic interactions between them. We found that the epistasis between DHFR 25 mutations is high-order for catalytic power of DHFR (k cat and K m ), but less prevalent for 26 trimethoprim affinity (K i ). Taken together our data provide a concrete illustration of how epistatic 27 coupling at the level of biochemical parameters can give rise to complex fitness landscapes, and 28 suggest new strategies for developing mutant specific inhibitors.
Resistance-conferring mutations have diverse effects on catalytic efficiency of DHFR.

163
Ideally, fitness effects of mutations should be measured at the organismal level. However, 164 characterizing the evolutionary fitness landscape for DHFR requires reliable fitness 165 measurements which is not always possible when in vivo assays are utilized. First, in our 166 experience, several of the bacterial mutants carrying DHFR mutations survived even at the 167 highest possible trimethoprim concentrations we could achieve (~3mg/ml) making it impossible to 168 measure their true resistance levels [15] . Second, despite our numerous attempts, it was not 169 possible to engineer some of the E. coli strains with desired combinations of DHFR mutations, 170 implying that cells with some DHFR alleles may not be viable [15] . Third, the strain we engineered 171 by replacing the endogenous folA (the gene that is transcribed into DHFR) with the wild-type folA 172 gene had a growth defect compared to its ancestor MG1655 strain making growth rate 173 measurements less reliable. Fourth, overexpression of DHFR due to promoter mutations masked 174 the true fitness effects of mutations found in the coding region of DHFR [15] . Finally, it is difficult 175 to unequivocally attribute the effects of mutations to bacterial fitness as bacterial cells can 176 compensate deleterious effects of DHFR mutations by gene regulation or rearranging metabolic 177 fluxes. Therefore, we decided to characterize fitness effects of DHFR mutations at the protein 178 level by utilizing in vitro assays.
179
We developed a rapid assay for calculating k cat , K m , and K i values for mutant DHFR enzymes 180 ( Figure 2 ). Measuring substrate affinity (K m ) and catalytic rate (k cat ) of an enzyme typically requires 181 enzymatic activity measurements at various substrate concentrations and predicting k cat and K m 182 values by fitting a Michelis-Menten function to the resulting data [7, 35, 36] . Depending on the 183 enzyme, this can be a laborious and expensive task. In the case of DHFR, the standard assay 184 used for measuring DHFR activity benefits from spectroscopic changes in the cofactor (NADPH) 185 and substrate (DHF) of DHFR as THF is produced. Typically, by maintaining a high concentration 186 of NADPH compared to the DHF, initial reduction rate of DHFR is calculated by monitoring the 187 absorbance of NADPH and DHF at 340 nm wavelength. NADPH and DHF have high absorptions 188 at 340nm (A 340 ) but their absorptions become insignificant upon hydride transfer between them.
189
When DHFR is mixed with NADPH and DHF, A 340 rapidly reduces until DHF is completely 190 consumed and this measurement needs to be repeated at several different substrate 191 concentrations for predicting k cat and K m values. We realized that this laborious assay was not 192 necessary for characterizing DHFR. In the presence of saturating concentrations of DHF (10- 195 Also, the spectroscopic properties of NADPH and DHF allow us to predict both DHF and NADPH 196 concentrations during the progression of this reaction. Since the rates of reverse reactions ( Figure   197 2A, counterclockwise direction) in the catalytic cycle are very slow relative to the forward reaction 198 rates (Figure 2A , clockwise direction), it is possible to calculate reaction rates at various DHF 199 concentrations from a single reaction progression curve. As shown in Figure 2B , we split the 200 progression curve in equal time windows and calculate corresponding mean DHF concentrations 201 and DHF reduction rates for every time interval. We then use these values to predict k cat and K m 202 values by fitting a Michelis-Menten equation (Figure 2C ). The K m values we measured using this 203 practical method were consistent with the values we measured using the standard conventional 204 method that needs measurements at several different DHF concentrations (K m predicted using 205 traditional method: 3.40±0.95µM, and our method gives: 2.86±0.97µM). In addition, by measuring 206 DHFR activity at steady state using various trimethoprim concentrations ( Figure 2D ), we 207 calculated trimethoprim (TMP) affinities of DHFR mutants (K i ) assuming competitive binding 208 kinetics between DHF and TMP ( Figure 2E 
210
All of the mutations except the L28R caused significant reductions in the substrate affinity 211 (increased K m ) of DHFR ( Figure 2F , Table S2 ). Contrary to our expectations, substrate affinity of 212 the L28R mutant was significantly increased (decreased K m ) relative to the wild type DHFR.
213
Changes in the K m were generally accompanied with significant changes in the k cat values.
214
Interestingly, three of the mutants (P21L, L28R, and R98P) exhibited decreased catalytic rates 215 whereas others (D27E, W30G, and W30R) had increased catalytic rates k cat . Finally, all of the 216 mutations but one (M20I) had reduced trimethoprim affinity (increased K i ). Although antibiotic 217 resistance via target modifications is typically attributed to reduced drug and substrate affinities 218 due to mutations, our measurements summarized in Figure 2F suggest that there could be distinct 
237
We utilized molecular dynamics (MD) simulations in order to study the structural changes 238 associated with the trimethoprim resistance conferring mutations in DHFR resulting from point 239 mutations discussed in the previous subsection ( Figure 2F ). E. coli DHFR is formed of eight 240 stranded β-sheets and four contiguous α-helices [37] [38] [39] . The enzyme is divided by the active site 241 cleft into two subdomains: the adenosine binding subdomain and the major subdomain. The
242
former (residues 38-88) provides the binding site for the adenosine moiety of the cofactor 243 (NADPH) and includes the CD loop (residues 64-71). The latter subdomain consists of ~100 244 residues and contains three loops on the ligand binding face that surrounds the active site. These 245 loops are known as M20 (residues 9-24), FG (residues 116-132), and GH (residues 142-150)
246
loops. The M20 loop is located directly over the active site, protecting it from the solvent, and is 247 involved in the regulation of the active site [37] . The M20 loop is found in three conformations 248 which are named as the open, occluded, and closed states [37, 40] . In our structural analysis, we 249 have used the structure (PDB ID: 1rx2) that has the closed M20 loop conformation [37] . For each 250 of the eleven mutants listed in Figure 2F as well as the wild type DHFR, we compiled 210 ns long 251 MD simulations for both the DHFR/NADPH/DHF (green in Figure 2B ) and the 252 DHFR/NADPH/trimethoprim complexes (Materials and Methods) [41] .
253
We have closely monitored the WT and all 11 single mutant sets of MD trajectories corresponding 254 to those listed in Figure 2F to decipher the molecular mechanisms that lead to trimethoprim 255 resistance. We note that while these mutations are observed with various frequencies in the 256 morbidostat trajectories as displayed in Figure 1D , nine of them appeared as the first coding 257 region mutation. Besides, the changes in the dynamics of the system due to resistance-conferring 258 mutations are usually subtle. In particular, the effect on trimethoprim binding is indistinguishable 259 in all DHFR/NADPH/trimethoprim complex simulations. This is expected since the free energy 260 difference implied by the K i changes reported in Figure 2F 
271
utilized for rendering DHF more effective than trimethoprim ( Figure 3 ).
272
In figure 3, we display resistance mechanisms for the D27E, L28R, and W30R mutations.
273
Amongst the wild-type (WT) and all the single mutants we analyzed, the D27E mutant is the only 274 one where the hydride transfer distance is kept at an optimal pre-catalytic range ( Figure 3A ). We 275 note that in all mutations we studied, the M20 loop never leaves the closed conformation in favor 276 of the occluded form which triggers the reduction of DHF into THF. Nevertheless, the longer side 277 chain of the D27E mutant dynamically maintains the ligand at an optimal distance, keeping it 278 ready for the hydride transfer once this rare event takes place, hence explaining the increase in 279 k cat for the D27E mutant ( Figure 2F ). On the other hand, the L28R mutation leads to the formation 280 of extra hydrogen bonds between the enzyme and DHF, thus stabilizing its conformation [41] . In 281 figure 3B, we display the average distance of hydrogen bonds formed between the enzyme and 282 DHF. We find that while the pterin tail of DHF is permanently engaged in the binding pocket (as 283 evidenced by the hydrogen bond distances to I5 and D27), the p-aminobenzoyl glutamate tail is 284 mobile in the wild-type (WT) DHFR. In contrast, this mobility is significantly reduced in the L28R
285 mutant due to the extra interactions provided by the side chain. Unlike D27E and L28R, the effect 286 of W30R on the dynamics of DHF is indirect. In this case, the R30 side chain of the mutant forms 287 a salt bridge with the side chain of E139 residing on the b sheet supporting the catalytic region 288 ( Figure 3C ). The distance between the two residues is reduced from a baseline value of ~8 Å to 289 ~2 Å. This interaction slightly opens the tight binding pocket so that the DHF p-aminobenzoyl 290 glutamate tail motions are accommodated in the region between R52 and R57 residues, whereas 291 the glutamate tail is more disordered and closer to R52 residue in the wild-type DHFR. Reduced
292
interactions between the p-aminobenzoyl glutamate tail and the enzyme leads to weaker 293 substrate binding and higher catalytic rate.
294
To summarize our experimental and computational findings thus far, we conclude that the effect 295 of single DHFR mutations on trimethoprim binding is not definitive for survival. It is rather the small 296 changes on the binding kinetics of the substrate (DHF) that provide the enzyme a small advantage 297 that is utilized for bacterial survival. Furthermore, the changes in the DHF binding dynamics 298 induced by single mutations are diverse. In the rest of the manuscript, we discuss the changes in 299 the fitness landscapes due to the accumulation of multiple mutations using a library of combined 300 mutants selected from a subset of those observed in the morbidostat trajectories.
302
Trimethoprim-free enzymatic velocity of DHFR mutants correlates well with trimethoprim-303 free growth rates of E. coli mutants carrying corresponding DHFR mutations.
304
Resistance-conferring mutations are rarely found in natural bacterial isolates and this observation 305 is generally attributed to the fitness costs of resistance-conferring mutations. In the case of 306 enzymes such as DHFR, where multiple resistance conferring mutations are sequentially fixed, it 307 is not clear how that many mutations can be tolerated and yet sufficient enzymatic activity is 308 maintained for organismal survival. To address this question, we selected six of the mutations 309 listed in Figure 2F (P21L, A26T, L28R, W30G, W30R, and I94L) and synthesized a DHFR mutant 310 library where we had all 48 (3 1 x2 4 ) possible combinations of these mutations. We purified and 311 characterized all of the mutant DHFR enzymes as previously described (Table S3 ). Next, we 312 measured growth rates of the E. coli mutant library ( Figure 4A ) that carry the same DHFR 313 mutations in various conditions (different temperature, different glucose concentrations, and 314 different casamino acids concentrations) ( Figure 4B -F). We found that enzymatic activity of DHFR 315 mutants in the absence of trimethoprim (V 0 , equation 1), calculated at saturating [DHF], correlated 316 well with the trimethoprim-free growth rates of E. coli mutants with corresponding DHFR mutations 317 (r = 0.46-0.58, p < 10 -3 , Pearson Correlation Test). The correlations between growth rates and 318 other biochemical parameters such as k cat or k cat /K m were less significant (for k cat : (r = 0.33, p < 319 10 -3 ); for k cat /K m : (r = 0.06, p < 10 -3 ), Pearson Correlation). We note that the 12.5µM DHF 320 concentration is in good agreement with the previously measured in vivo DHF concentrations in 321 which both reduced and oxidized species of folate concentrations were in the range of ~10 µM 322 [42] . These experiments and the resulting analysis suggested that V 0 , the substrate reduction rate 323 of DHFR in the absence of trimethoprim, is a good predictor of bacterial fitness, particularly when limited nutrients are provided to bacterial populations (i.e., minimal media supplemented with 325 0.4% glucose) and bacterial cells are grown in the absence of trimethoprim.
326
Combined effects of resistance-conferring mutations deviate from fitness values predicted 327 by Bliss Additivity.
328
In order to qualitatively understand the evolutionary trade-offs in DHFR evolution, we plotted V 0 329 values against the corresponding K i values for DHFR mutants. Interestingly, V 0 values exhibited 330 a bifurcation in this geometric representation ( Figure 5A ). DHFR mutants either had enzymatic 331 activities comparable to their wild type ancestor or significantly lost their enzymatic activities,
332
displaying almost no activity. Interestingly, all of the mutants that were funneled into the highly 333 decreased enzymatic activity regimen carried the P21L mutation ( Figure 5A , red triangles and 334 circles). In addition, none of the mutants that were detected in the morbidostat ( Figure 5A , grey 335 and red circles) had V 0 values lower than four percent of the wild type V 0 ( Figure 5A , horizontal 336 dashed line). We note that all of the DHFR alleles observed in the morbidostat appeared in the 337 background of a promoter mutation that increases DHFR amount by 10-20 fold ( Figure 1B , insert).
338
Therefore, all the observed mutants in the morbidostat are predicted to have DHFR activity 339 equivalent to 40-80 percent of the wild type DHFR (V 0 ).
340
In order to test the existence of epistatic interactions among DHFR mutations, we asked whether 
346
[43], the predicted K i and V 0 values were significantly different from the experimentally measured 347 ones (Student t-test, p<10 -3 ; Figure S1 , Table S3 ). We also found that the predicted V 0 values did 348 not display a bifurcation and steadily declined as the number of DHFR mutations increased. We 349 also found that the predicted K i values were not as large as the experimentally measured values 350 ( Figure 5 A-B ). When we instead utilized the mean effects of single mutations on all possible 351 genetic backgrounds in our mutant library ( Figure 6 ), we were able to better estimate the K i values 352 ( Figure 5C ). However, the bifurcation we observed in Figure 5A 
358
Effects of mutations on the catalytic power of DHFR were largely context dependent due 359 to epistasis between mutations.
360
We calculated (geometric) mean phenotypic effects of individual DHFR mutations on K m , k cat , and 361 K i and V 0 values (Table S3 ). Briefly, for every single amino acid replacement in DHFR, we divided 362 the DHFR mutant library into two groups depending on whether they have a particular mutation 363 (i.e. P21L, Figure 6A ) and compared the K m , k cat , K i , and V 0 values of the two groups. Thus, we 364 were able to calculate mean fold changes in K m , k cat , K i , and V 0 values due to a single mutation 365 as shown in Figure 6B . This analysis clearly showed that all six of the mutations we analyzed 
374
Epistasis between resistance-conferring DHFR mutations is high-order for substrate 375 binding and catalysis (k cat and K m ) but first-order for drug binding (K i ).
376
We quantified epistatic interactions between the six DHFR mutations (P21L, A26T, L28R, W30G,
377
W30R, and I94L) we studied by utilizing a linear regression model (Materials and Methods) [44] ).
378
Briefly, we attempted to recover fitness values of all DHFR alleles using epistatic terms between 379 mutations. In a biological system, if the epistasis between mutations is large, it is difficult to 380 recover fitness values for genotypes with n mutations by using up to m th order epistatic terms (m 381 < n). However, if epistatic interactions are less prevalent, predicting fitness of genotypes by using 382 up to m th order epistatic terms (m < n) becomes more feasible. As shown in Figure 7A , we were 383 able to adequately predict K i values for all DHFR mutants with up to five mutations by using only 384 the first order epistasis terms (~10-20% residual error). The extra information we gain from using 385 higher order epistatic terms was relatively small ( Figure 7B) we had for K i , we needed to use at least up to third order epistatic terms and yet there was a big 393 variance in the prediction performance ( Figure 7B ). This suggested that the effects of the 394 mutations on DHFR's catalytic activity were highly context dependent which make fitness 395 landscape of DHFR rugged [15] . We conclude that the epistasis between resistance-conferring 396 mutations is high-order for k cat and K m but first-order for K i values. 
409
L28R and I94L. In addition, we traced the effect of adding P21L mutation to some of these mutants 410 in order to understand how adding the P21L mutation drastically reduces enzymatic efficiency 411 (Figures 5 and 6) . Amongst these, L28R is frequently observed as the first coding region mutation 412 in the morbidostat while A26T and I94L are observed later in evolution experiments (Table S5 ).
413
We demonstrate the context dependence of the observed dynamics by focusing on four specific 414 examples involving double mutations in Figure 8 . We traced the signature hydrogen bonds 415 between the enzyme and the substrate ( Figure 8 ) and found that hydrogen bonds between the I5 416 and D27 side chains in the studied mutants were always close to their native values in the wild 417 type DHFR. However, the hydrogen bonds between the R52 and R57 side chains and DHF 418 showed significant variations (displayed in figure 8 , averaged over the last 100 ns of the 419 trajectories.) For the single mutants, we do not find any significant dynamical changes in the MD 420 trajectories for P21L and A26T mutations. We note that the common reduction in the k cat value due to the P21L mutation ( Figure 2F ) implied that the effect of this mutation is mainly in the 422 dynamics of the catalytic M20 loop, whose dynamics is on the time scale of seconds and is 423 therefore not within the sub-microsecond observation window of our MD simulations. Meanwhile, 424 the I94L mutant completely loses interactions with the R57 side chain since the slight change in 425 the isomerization of the side chain leads to more prolonged interactions with the aromatic ring of 426 DHF, distorting the tight binding pocket. As a result, the R57 side chain flips out of the pocket to 427 the other side of the helix spanning residues 25-37 (figure 8A).
429
As was previously described in figure 3B , L28R mutation leads to the formation of extra hydrogen 430 bonds with DHF. We found that together with A26T, this effect becomes even stronger, fixing the 431 position of DHF to the space between R52 and R57 residues (figure 8B 
448
On the other hand, we do not observe significant structural fluctuations in DHFR upon 449 trimethoprim binding unless more than two mutations are accumulated. With the introduction of a 450 third mutation, the dynamics of the DHFR is significantly altered, with amplified motions observed 451 in the loops. In Figure S2A along with a substantial increase in the amount of fluctuations; the effect is magnified as more mutations are accrued. In fact, the RMSF of multiple mutants are well correlated with log K i values 455 as displayed in Figure S2B , (multiple mutants: r = 0.70, p < 0.01; all cases including WT: r = 0.60, 456 p < 0.01; Pearson Correlation). Thus, the effect of decreased inhibitor binding affinity is significant 457 for reinforcing resistance in higher number of mutants, while the first two mutations are more 458 effective in the catalytic activity.
459
Promoter mutations compensate detrimental effects of several mutations and largely 460 increases number of plausible evolutionary trajectories.
461
Evolution of trimethoprim resistance is a random search for mutational trajectories that lead to the 462 resistant DHFR genotypes without sacrificing catalytic activity. We ran computer simulations to 
471
which is in the physiological range and we assumed a ten-fold increase in DHFR expression due 472 to the promoter mutation ( Figure 1B) . Alleles are grouped according to the number of mutations 473 they have. We then ran stochastic simulations where we consider the DHFR sequence as a lattice 474 and allow DHFR to acquire mutations as trimethoprim dosage is gradually increased. All 475 simulations start from the wild type DHFR allele and the activities of all DHFR alleles are 476 calculated at every trimethoprim concentration. In these simulations, we assume that any DHFR 477 mutant that has activity (V) less than half of the wild type DHFR activity (V 0 WT , no trimethoprim) 478 goes extinct unless they acquire a beneficial mutation. In our simulations, we allow DHFR to 479 obtain or lose one of the seven mutations (promoter, P21L, A26T, L28R, W30G, W30R, and I94L)
480
if activity of the mutant is about to drop below half of V 0 WT . Any of these mutations can be added,
481
converted (W30R à W30G, W30G àW30R) or reverted (e.g. L21 mutant to P21). As shown in 482 Figure 9 , we observed several genetic trajectories that arrive at local or global maxima. We 483 repeated these simulations 10 6 times and quantified relative abundance of mutational trajectories 484 ( Figure 9 and Table S6 ).
485
Mutational trajectories that lead to high trimethoprim resistance peaks typically accumulated up 486 to five mutations and the majority of these trajectories reached to the fitness peaks in five to seven 487 genetic steps. Several viable trajectories included more than five mutational steps mainly because 488 reverting the P21L mutation back to wild-type (L21P) significantly improved DHFR fitness in 489 several genetic backgrounds. We then ranked all of the genetic trajectories that reach to high 490 trimethoprim resistance by taking the least possible number of steps and calculated the likelihood 491 of each mutation in the adaptive landscape (Table S6 ). We have also repeated these simulations 492 using lower fitness thresholds (i.e. 1% of V 0 for the wild type DHFR) and showed that number and 493 length of evolutionary trajectories that reach to fitness peaks drastically increase if minimum 494 fitness thresholds are assumed to be lower ( Figure S3 ).
495
Finally, we computationally tested the effect of promoter mutations in DHFR evolution ( Figure   496 9C). To do this, we ran simulations where all of the DHFR alleles with promoter mutations were 497 eliminated and we compared these simulations with those that allow the promoter mutation. We
498
found that number of plausible mutational trajectories that lead to trimethoprim resistant 499 genotypes significantly diminishes if the promoter mutation is not allowed ( Figure 9C ). When 500 promoter is not allowed, only 1.289 ± 0.005% of the simulated trajectories reach to genotypes 501 that survived in 32 µM trimethoprim which is considered as resistant in clinical microbiology 502 laboratories. There are only 60 unique trajectories which acquired one or more DHFR mutations 503 and increased trimethoprim resistance. However, when promoter mutation is allowed, 5.592 ± 504 0.026% of the simulated trajectories reach to genotypes that survived in trimethoprim 505 concentrations between 32 µM and ~2.58mM. In this case, 2573 unique trajectories acquired one 506 or more DHFR mutations and increased trimethoprim resistance. This effect is mainly due to 507 elimination of half of the possible genetic combinations between the six resistance-conferring 508 mutations we studied and also elimination of the compensatory effect of the promoter mutation.
509
Thus, number and length of plausible evolutionary trajectories, as well as the maximum possible 510 trimethoprim resistance significantly diminish in the absence of the promoter mutation. Therefore,
511
in the absence of promoter mutation, DHFR evolution becomes more predictable. As a result, 512 being able to target the promoter mutation with one of the novel gene editing methods together 513 with a mutant-specific drug that specifically inhibits a mutation such as L28R, that is a synergistic 514 mutation, might significantly slow down evolution of trimethoprim resistance. We note that 515 eliminating the promoter mutation or the L28R mutation does not exclude other evolutionary 516 solutions such as acquiring other resistance conferring mutations listed in Figure 2F , gene 517 duplication, and acquiring other promoter mutations.
518
We conclude that, although expected to be random, the first plausible mutation in DHFR evolution 519 is expected to be one of the promoter, W30R, or W30G mutations. Indeed, the c-35t and W30R 520 mutations were previously found in clinically isolated E. coli strains [45] . Due to epistatic 521 interactions, evolutionary trajectories become more constrained after acquiring the second and 522 third mutations. However, the promoter mutation makes the adaptive landscape of DHFR less 523 predictable by compensating for diminished catalytic activities of resistance-conferring DHFR 524 mutation(s).
525
Discussion: 526
DHFR is a ubiquitous enzyme commonly used as a drug target in antibacterial, anticancer, and 527 antimalarial therapies [21] . Developing a better understanding of the evolution of drug resistance 528 through sequential accumulation of DHFR mutations is therefore an important scientific task to 529 help improve drug therapies. Our experimental findings and computational analyses demonstrate 530 that DHFR is a highly evolvable enzyme that can maintain its catalytic activity while accumulating 531 multiple resistance-conferring mutations. Throughout the evolution of trimethoprim resistance in 532 E. coli, DHFR can accumulate mutations in at least ten residues and four different promoter that the epistasis comes from non-linearities in the fitness [46] . Conversely, in this study, by 546 utilizing both biochemical assays and growth rate measurements, we deconvolved epistasis 547 between resistance-conferring mutations and demonstrated that epistasis was largely due to 548 changes in catalytic activity of the mutant DHFR enzymes rather than nonlinearity in bacterial 549 fitness. We also showed that epistatic interactions and the compensatory effects of promoter 550 mutations significantly diminish our ability to predict DHFR evolution in the presence of 551 trimethoprim induced selection.
552
In a recent study, Rodrigues et al. investigated epistasis between three of the mutations we 553 studied (P21L, L28R, and W30R) and developed an elegant framework to predict fitness of E. coli 554 strains carrying DHFR alleles with combinations of these three mutations by using biophysical 555 properties of DHFR mutations [7] . However, because of the low number of possible combinations 556 (2 3 ) of DHFR mutations they studied, they were not able to observe the P21L-caused bifurcation 557 in the fitness landscape we report here ( Figure 5) . Therefore, for a larger set of combinations of 558 DHFR mutations that include the P21L, fitness prediction of DHFR alleles will naturally be more 559 difficult. Using the available biochemical fitness values we have, we were able to identify partial 560 correlation between catalytic power and bacterial growth rates of DHFR mutants. However, we 561 were not able to demonstrate a direct correlation between trimethoprim resistance and 562 biochemical parameters we measured. We note that predicting trimethoprim resistance levels 563 might be possible by using extra biophysical parameters such as thermal stability and abundance 564 of DHFR mutants as was demonstrated by Rodrigues et al. [7] .
565
Our analysis suggests that although predicting DHFR evolution is a difficult task, it might still be 566 possible to steer evolution of trimethoprim resistance towards clinically less challenging 567 phenotypes. Among all the mutations we studied, promoter and L28R mutations can potentially 568 be targeted to reduce the number of plausible evolutionary trajectories and trimethoprim 569 resistance. For example, being able to specifically target the promoter mutation by utilizing one 570 of the novel gene editing tools will substantially decrease both the number of accessible 571 trajectories and maximum resistance levels (Figure 9 ) [47] . Also, since the L28R mutation has a 572 distinct molecular mechanism that increases its relative preference for the substrate over the drug 573 molecules (Figure 3) , it might be possible to design L28R-specific DHFR inhibitors that will mimic 574 DHF without losing its specificity against bacterial DHFR. Since L28R mutation is observed in 575 almost 80 percent of all morbidostat trajectories and is synergistically interacting with several 576 mutations, an L28R specific inhibitor will substantially impede evolution of trimethoprim 577 resistance.
578
Materials & Methods: 579 580
Growth Rate Measurements
581
All DHFR mutant strains were constructed in MG1655 attTn7::pRNA1-tdCherry (gift from Johan Paulsson).
582
Detailed procedures for making mutant strains can be found [15] . Bacterial cultures were grown at 30 °C in 583 M9 minimal medium supplemented with 0.4% glucose (Fisher Scientific B152-1 
612
is consumed which happens when the curve reach a plateau down below zero. Data analysis is done as 613 explained in the main text (Figure 2A-B ).
615
Inhibition constant (K i ) for TMP Determination
616
To calculate inhibition constants for TMP, we used initial rates of the reactions with saturating 617 concentrations of DHF and NADPH with different TMP concentrations. These initial rates used to fit 618 Michelis-Menten competitive inhibition formula to calculate K i values ( Figure 2C-D) . 
631
Epistasis Calculations and Linear Regression Model
632
A linear regression model is used to recover fitness of DHFR alleles by using epistatic interactions terms 633 between DHFR mutations. The theory and algorithm we used to calculate epistatic terms and perform linear 634 regression is described in detain by Poelwijk et al. [44] .
636
Molecular Dynamics Simulations
637
The NAMD package is used to model the dynamics of the protein-water systems [48] . Solvation is achieved via 638 the VMD 1.9.1 program solvate plug-in version 1.2 [49] . The protein is soaked in a cubic solvent box such that 639 there is at least a 10 Å layer of solvent in each direction from any atom of the protein to the edge of the box. The 640 system is neutralized and 150 mM of ionic strength in all the simulations is maintained by adding a suitable number 641 of K + and Cl ions. The CharmM22 all-atom force field is used to model the protein and the TIP3P potential for 642 water [41, 50] . We have adopted the force field parameters for 5-protonated 7,8-dihydrofolate and trimethoprim . Pressure control is attained by a Langevin piston.
648
All systems are first subjected to 10000 steps of energy minimization with the conjugate gradients algorithm. The
649
resulting structures are then run in the NPT ensemble at 1 atm and 310 K until volumetric fluctuations are stabilized 650 and the desired average pressure is maintained.
651
MD simulation of the ternary complex of the DHF bound systems are constructed based on the crystallographic 652 structure with PDB code 1rx2 [37] . DHFR is complexed with folate and oxidized NADP (NADP + ) in this native 653 form. We protonate NADP and folate so that the former is in the reduced form (NADPH) and the latter is 5-654 protonated 7,8-dihydrofolate to model the stable state prior to the hydride transfer step.
655
In a separate set of MD simulations, we study the effect of trimethoprim binding in its unprotonated (TMP) or 
665
The mutants studied are as follows: The single mutants I5F, M20I, P21L, A26T, D27E, L28R, W30G, W30R,
666
I94L, R98P and F153S; all double mutant combinations of the A26T, L28R, I94L sets; the A26T-L28R-I94L triplet;
667 the A26T-L28R-W30R-I94L and the A26T-L28R-W30G-I94L quadruplet. Also, to test the effect of the P21L 668 mutation, we have studied the double mutant combinations of P21L with each of A26T, L28R, I94L as well as the 669 P21L-A26T-L28R, P21L-A26T-I94L and P21L-L28R-I94L triplet, P21L-A26T-L28R-I94L quadruplet; and the 670 P21L-A26T-L28R-W30R-I94L and the P21L-A26T-L28R-W30G-I94L quintets. Thus, we have carried out 210 ns 671 long simulations of 26 sets of mutants, with DHF, TMP and TMP + bound, leading to simulations exceeding 17.6 672 µs, including the WT sets.
673
We use the approach in reference [41] to confirm the native form of trimethoprim in the DHFR bound state, by 674 monitoring the distribution of the native hydrogen bonds in the binding pockets. In all the sets, TMP + remains 675 tightly bound while TMP flips in and out of the binding pocket throughout the simulation. We thus accept the 676 protonated form of trimethoprim to be the native form in all the systems; note that this is not the case for D27N 677 and D27S mutants, as discussed at length in reference [41] .
679
Simulations of Protein Evolution and Visualization
680
Protein evolution simulations works on a DHFR mutational lattice (proteins as nodes and single mutation 681 acquisition, conversion or reversion as lines). Simulations starts from WT in no trimethoprim condition.
682
Trimethoprim concentration gradually increases and at each drug concentration fitness landscape of DHFR 683 lattice is calculated. When drug concentration hits a value where enzyme activity is lower than threshold 684 activity (50,10,1,0.1% of WT enzyme activity at [TMP] = 0 nM) a random mutational step is taken (a mutation acquisition, conversion or reversion). If the new mutant has lower activity than threshold, the simulation 686 stops, otherwise the new mutation is fixed, and drug concentration starts increasing again till new mutants' 687 activity drops down to the threshold level ( Figure 9B ). Simulations are repeated for a million times to sample 688 all possible unique trajectories. Python scripts to run the simulation is added to supplementary files. -35t, g-31a) lead to 10 to 20-fold higher DHFR expression relative to WT. C) Mutated DHFR residues are highlighted in different colors on DHFR structure (PDB ID: 1rx2). D) Observed frequencies of resistance conferring mutations plotted for 33 independent morbidostat experiments (28 populations from this study and 5 populations from a previous study [26] ). Endogenous folA gene was replaced with the wild-type (WT) or mutated folA genes (Materials and Methods). Cells were grown at ~30ºC in minimal M9 media supplemented with 0.4% glucose and 0.2% amicase in 12 replicates. Exponential growth rates of all mutants except the I5F and L28R are all significantly lower than the parental MG1655 E. coli strain but higher that the strain (WT) we engineered by reinserting the wild-type (WT) folA gene. Despite our several attempts, the engineered WT strain had a growth defect most likely as a result of the selection markers we used for cloning (Materials and Methods). (Lower Panel) All engineered E. coli strains carrying single DHFR mutations have elevated trimethoprim resistance. Inhibitory concentrations reducing growth by ninety percent (IC 90 ) were measured by growing mutants in a gradient of trimethoprim using 12 replicates (~30ºC in minimal M9 media supplemented with 0.4% glucose and 0.2% amicase). Student's t-test (two tailed) is used to quantify significance of IC 90 changes relative to the wild type (WT) DHFR (*: p<0.05; **: p<0.01; ***: p<0.001, error bars shows the standard error on the mean for each mutant). The measured distance is between the cyan and blue spheres shown in the inset for the crystal structure positioning of NADPH (black) and DHF, which is readily lost in the wild type structure as in all the other simulations of the single mutants except for D27E. Dynamical motions of NADPH and DHF are displayed on the right. (B) L28R mutations yields extra direct hydrogen bonds with DHF and stabilizes it in the binding pocket. The distance between the donors and acceptors of the hydrogen bonds originally present in the crystal structure is monitored throughout the MD trajectories with their averages and standard deviations displayed. While the original hydrogen bonds are lost in both the wild type and the L28R mutant, there are many new hydrogen bond donor sites on the R28 side chain, maintaining a dynamical hydrogen bonding ecology around the substrate. (C) W30R mutation releases the tension in the tight binding pocket by forming a salt bridge with E139. The distance between the E139 acceptor (O-group) and the closest heavy atom of residue 30 is plotted for the wild type and the W30R mutant. In the latter case a salt bridge is established between the side groups frequently, relaxing the tight binding pocket where the substrate resides. As shown on the right, DHF maintains a position between the stabilizing R52 and R57 side chains in the mutant while the contacts with R57 group is lost in the wild type. Figure S1 , Table S3 ). C) Predicted V 0 and K i values for multiple DHFR mutants by Bliss Independence model using the (geometric) mean effects of single mutations on all possible genetic backgrounds (Table S4 ). This model over-predicts K i values by a factor of 6 ±3.96 and under-predicts V 0 values by 0.35 ± 0.39 (Mean ± standard deviation; Figure S1 , Table S3 ). The bifurcation observed in panel A disappears in both analysis summarized in panels B and C.
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Figure Captions
Figure 6: Mean effects of DHFR mutations in catalytic activity and trimethoprim binding. A)
Each marker in upper panels show fitness changes when a mutant acquires P21L mutation. x axis shows K m , k cat and K i values of mutant alleles without P21L mutation and y axis shows the values mutant alleles with P21L mutation. For instance, the black encircled points has the K m , k cat or K i value of WT on x axis and corresponding values for P21L on y axis. B) Fold change effects when each single mutant is added on top of all other genotypes. Student's t-test (two tailed) is used to quantify significance of K m , k cat and K i , V 0 changes relative to the wild type DHFR (*: p<0.05; **: p<0.01; ***: p<0.001).
Figure 7: Epistasis between resistance-conferring DHFR mutations is high-order for substrate binding and catalysis (k cat and K m ). A)
A linear regression model is used to predict fitness information stored in epistatic terms with increasing orders. Correlations between predicted fitness values of all genotypes using n th order epistatic terms and the measured fitness values are calculated. B) Median residual errors for predicted fitness values as function of degree of epistatic terms used in regression. First order epistatic terms are sufficient to recover experimental K i values with ~10-20% residual error. However, at least second and third order epistatic terms are required to recover experimental K m and k cat values with with ~10-20% residual error.
Figure 8. Epistasis between resistance-conferring DHFR mutations are largely due to interactions of the mutated enzyme with the p-aminobenzoyl glutamate tail of DHF. (A)
The I94L mutation exacerbates substrate binding of DHFR by altering tight interactions with the p-aminobenzoyl glutamate tail of DHF in the binding pocket, allowing the R57 side chain to flip out. (B) L28R mutation is a highly epistatic mutation; together with either A26T or I94L, the L28R further stabilizes the substrate in the pocket. Note that the P21L-I94L double mutation also rescues the negative effect of I94L as traced through the hydrogen bond distances. Heights of the cylinders correspond to trimethoprim concentrations required to reduce the activity of mutant DHFR enzymes down to half of the V 0 for the wild type DHFR (V 0 WT ). Note that several pillars have zero height because their activities never exceed half of V 0 WT even in the absence of trimethoprim. The trajectory represented with solid arrowed lines is one of the shortest and most common pathways leading to global maximum of the adaptive landscape. The trajectory represented with dashed arrowed lines lead to a local maximum of the adaptive landscape if the promoter mutation is not allowed. B) Schematics summarizing the algorithm used in simulations. C) Simulations analysis summarized in heat maps. In simulations where the promoter mutation is not allowed (left), trajectories are shorter compared to the trajectories where the promoter mutation is allowed (right). If the promoter mutation is allowed, an increased number of trajectories lead to adaptive peaks with higher trimethoprim resistance levels.
Figure S1: Comparison of predicted V 0 and K i values using Bliss additivity with experimentally measured values. Panels on left side shows x-axis values predicted with a Bliss Independence model using single mutant data. Panels on the right shows x-axis values predicted with a Bliss Independence model using the (geometric) mean effects of single mutants.
Figure S2: RMSF of inhibitor bound DHFR obtained from MD trajectories is increased as new mutations are added to the protein. A)
Maximum fluctuations in a residue are less than 3 Å in the WT protein (two replica simulations); the L28R single mutation and the L28R-I94L double mutation display their largest motions in the same regions as the WT, albeit with larger amplitude; with the addition of more mutations, largest amplitude motions are increased in size along with the introduction of additional mobile regions. B) The maximum RMSF values calculated for all the systems studied via MD are well correlated with experimentally measured log(K i ) values for multiple mutant cases (filled circles; r = 0.71, p < 0.01) while they are uncorrelated for single mutants (r = 0.04, p > 0.9); overall correlations have r = 0.60; p < 0.01.
Figure S3: Simulations are repeated for different threshold values (%V 0 of WT as threshold)
showing the number and length of evolutionary trajectories that reach to fitness peaks drastically increase if minimum fitness thresholds are assumed to be lower. Table S1 : WGS results of last days of morbidostat experiments show coding region mutations mostly occurred on folA gene (encodes DHFR). Table S2 : Mean measured K m , k cat , and K i values of single mutants are shown in the table with standard error of the mean. Additional sheets show measured replicates separately for each parameter (K m , k cat and K i ). Table S3 : Summary of all measured K m , k cat , and K i values for combination dataset. This excel file also shows the Bliss Additivity calculations of K m , k cat , and K i for both models with Single Mutant data and Mean Effects of Single Mutants. Table S4 : Effects of addition of a single mutant in all backgrounds are shown as a table. This data is plotted in Figure 6B . Table S5 : Single mutants are appeared at different times in the morbidostat experiment. Table shows the number of times each single mutant is appeared as the first coding sequence mutation. In the morbidostat experiment in almost all the cultures end with a single genotype dominating the culture. Second data column in this table shows the number of times a mutant is appeared in the last day of the evolution experiment. Table S6 : Probability of seeing a mutant in the simulations are put in this table. Each column shows different threshold (%V 0 of WT as threshold) and whether the promoter mutation is allowed in the simulation. 
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